BioMedNewsBreaks Archive - Page 96 of 234

WednesdayJul 19, 2023 1:42 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its entry into definitive agreements with health care-focused institutional investors. The agreements are for the sale and issuance of 7,425,744 shares of the company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $0.885 per share, exercisable at the date of issuance…

TuesdayJul 18, 2023 1:37 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has signed an exclusive license agreement with the University of Pittsburgh. The agreement grants Genprex worldwide, exclusive rights to a patent application and related technology for a gene therapy targeting both type 1 and type 2 diabetes. The therapy utilizes Pdx1 (“Pdx1”) and MafA (“MafA”) genes controlled by an MafB (“MafB”) promoter and administered through an adeno-associated virus (“AAV”) vector directly into the pancreatic duct. Preclinical data from nonhuman primate models of type 1 diabetes show promising results, with significant decreases…

TuesdayJul 18, 2023 1:19 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Presenting 6 Posters on Its Lead Therapeutic Candidate at AAIC 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced that it is presenting six in-person posters highlighting data from its phase 1 clinical trials investigating the company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”). The event is taking place July 16-20, 2023, in Amsterdam, Netherlands. “We are honored to have six posters accepted for presentation at AAIC 2023, a prestigious meeting of leading Alzheimer’s disease experts and pharmaceutical innovators,” said Ram Mukunda, CEO of IGC. “The data being presented at AAIC from our phase 1 clinical trial of IGC-AD1 demonstrates the positive impact of…

TuesdayJul 18, 2023 1:02 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that an arbitration panel has found that Syneos Health (NASDAQ: SYNH) failed to use commercially reasonable efforts in conducting its trial for FSD 201. According to the announcement, Syneos Health filed an arbitration proceeding against FSD Pharma in 2022. Syneos claimed that FSD Pharma owed Syneos Health $3,915,388.69 in damages as well as interest on that amount in relation to a failed phase 2 FDA trial…

MondayJul 17, 2023 2:15 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, anti-PD1 resistant, human NSCLC metastases in humanized mouse models, presenting the data at the 2023 American Association of Cancer Research (‘AACR’) annual meeting, held in April,” reads a recent article. “According to Genprex President, Chairman and CEO Rodney Varner, the use of ONCOPREX(R) to deliver…

MondayJul 17, 2023 1:12 pm

BioMedNewsBreaks – Institute of Biomedical Research Corp. (MRES) Unveils Meticulously Crafted Line of Teas Sourced from Kenya

Institute of Biomedical Research (OTC: MRES) (doing business as M2Bio Sciences) is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence and evidence-based sustainable products and solutions. M2Bio Sciences today announced the forthcoming launch of a captivating line of teas sourced from the scenic gardens of Kenya. The meticulously crafted collection provides not only an exquisite sensory experience but also delivers exceptional medicinal health benefits. “We are delighted to introduce our exceptional line of purple, white and green teas from Kenya,” said Jeff Robinson, CEO of M2Bio Sciences. “Our…

WednesdayJul 12, 2023 11:32 am

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Financial Results for Fiscal 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug formulations through FDA trials,” said Ram Mukunda, CEO of IGC. “IGC-AD1 is delivering strong results as it progresses through phase 2B trials. We are delighted with the positive headway we are making in clinical trials, and we remain confident in the potential of IGC-AD1 to be a groundbreaking therapy, with the potential to treat Alzheimer’s and to manage devastating symptoms…

TuesdayJul 11, 2023 2:06 pm

BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Announces New Findings to Be Presented at Annual AAIC

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced new findings from data to be presented at the annual Alzheimer’s Association International Conference (“AAIC”). Slated to take place in Amsterdam, Netherlands, AAIC is the largest medical meeting focused on Alzheimer’s disease (“AD”). “One of the difficulties in developing drugs for AD is the inability to quantify the disease and measure changes at the tissue or microstructure level. The current approaches to measure brain changes utilize imaging techniques that measure the whole brain,” said RJ Tesi,…

TuesdayJul 11, 2023 1:31 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Expands C-Suite to Welcome Key GBB Drink Lab Execs

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that, along with the asset purchase agreement for the company’s purchased and provisional patents, two GBB Drink Lab executives will join Jupiter Wellness’ C-suite. Josh Wagner, the former U.S. director of sales for Anheuser Busch, where he led a $12 billion business with a 72 person sales team to their best performance since 2009, will serve as Jupiter Wellness’ chief revenue officer. In addition, David Sandler, the former COO and CSO of several supplement brands that exceeded $75 million in revenue, will serve as the company’s…

TuesdayJul 11, 2023 1:13 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Bell2Bell Podcast

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. BiondVax CEO Amir Reichman joined the program to discuss the company’s recent achievements. “At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Presenting 6 Posters on Its Lead Therapeutic Candidate at AAIC 2023

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline

BioMedNewsBreaks – Institute of Biomedical Research Corp. (MRES) Unveils Meticulously Crafted Line of Teas Sourced from Kenya

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Financial Results for Fiscal 2023

BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Announces New Findings to Be Presented at Annual AAIC

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Expands C-Suite to Welcome Key GBB Drink Lab Execs

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Bell2Bell Podcast

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search